A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

NCT ID: NCT06343948

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 383 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-24
• Study Completion Date: 2026-05-31

Brief Summary

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy.

Conditions

HR+HER2- Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-B01D1

Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Eribulin or Vinorelbine or Gemcitabine or Capecitabine

Participants receive Eribulin or Vinorelbine or Gemcitabine or Capecitabine in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

Eribulin

Intervention Type: DRUG

Administration by intravenous bolus for a cycle of 3 weeks.

Vinorelbine

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Gemcitabine

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Capecitabine

Intervention Type: DRUG

Oral administration for a cycle of 3 weeks.

Interventions

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Eribulin

Administration by intravenous bolus for a cycle of 3 weeks.

Intervention Type: DRUG

Vinorelbine

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Gemcitabine

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Capecitabine

Oral administration for a cycle of 3 weeks.

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. Voluntarily sign the informed consent and follow the requirements of the protocol;

2. No gender limit;

3. Age ≥18 years old;

4. expected survival time ≥3 months;

5. Patients with unresectable locally advanced, recurrent metastatic HR+HER2- breast cancer;

6. The subjects had received 1-2 lines of chemotherapy regimens in the unresectable locally advanced recurrence or metastasis stage, and had been treated with endocrine, CDK4/6 inhibitors, and taxanes;

7. Documented radiographic disease progression;

8. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;

9. Must have at least one measurable lesion according to RECIST v1.1 definition;

10. ECOG score 0 or 1;

11. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

12. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

13. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;

14. Urine protein ≤2+ or < 1000mg/24h;

15. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and it must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. Prior receipt of an ADC drug with a topoisomerase I inhibitor as a toxin;

2. Prior receipt of an ADC or antibody drug targeting EGFR and/or HER3;

3. Chemotherapy, biological therapy, immunotherapy, etc., have been used within 4 weeks or 5 half-lives before the first dose, small molecule targeted therapy has been used within 5 days, palliative radiotherapy, modern Chinese medicine preparations approved by NMPA for anti-tumor therapy, etc., have been used within 2 weeks;

4. anthracycline equivalent cumulative dose of adriamycin > 360 mg/m2;

5. History of severe cardiovascular or cerebrovascular disease;

6. Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded;

7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

8. Other malignant tumors diagnosed within 3 years before the first dose;

9. Hypertension poorly controlled by two antihypertensive drugs; Patients with poor glycemic control;

10. A history of interstitial lung disease (ILD) requiring steroid therapy, current ILD or grade ≥2 radiation pneumonitis, or suspicion of such disease on imaging during screening;

11. Complicated pulmonary diseases leading to clinically severe respiratory function impairment;

12. Patients with active central nervous system metastases;

13. Patients with massive or symptomatic effusions or poorly controlled effusions;

14. Imaging examination showed that the tumor had invaded or wrapped around the large blood vessels in the abdomen, chest, neck, and pharynx;

15. Severe infection within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;

16. Was receiving &gt before randomization; Long-term systemic corticosteroid therapy with 10mg/ day prednisone or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;

17. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;

18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;

19. Patients with inflammatory bowel disease, extensive bowel resection history, immune enteritis history, intestinal obstruction or chronic diarrhea;

20. Have a history of allergy to recombinant humanized antibodies or to BL-B01D1 and any excipients; A history of autologous or allogeneic stem cell transplantation;

21. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;

22. A history of severe neurological or psychiatric illness;

23. Received other unmarketed investigational drug or treatment within 4 weeks before the first dose; A live vaccine dose within 28 days before the planned dose or the first dose;

24. Any complications or other circumstances deemed by the investigator to preclude participation in the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Binghe Xu

Role: PRINCIPAL_INVESTIGATOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

BL-B01D1-306

Identifier Type: -

Identifier Source: org_study_id